SCYNEXIS: SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

JERSEY CITY, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second-generation fungerp candidate SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) in Vienna, Austria being held from April 11-15, 2025.SCY-247 is being developed to address systemic fungal diseases, with a key focus on invasive fungal infections where resistance to current limited treatment options is a significant concern. These presentations at ESCMID Global 2025 continue to build upon SCY-247's positive preclinical data illustrating its unique attributes in the fight against difficult-to-treat fungal infections, including its potent antifungal activity against multi drug-resistant fungi.Poster Presentations:Title:Antifungal susceptibility testing of SCY-247 against contemporary clinical yeast isolatesPoster Number:P2909Session Title:06d. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)Session Date/Time:Saturday, April 12 at 12:00 pm CETPresenting author:Luis Ostrosky-Zeichner MD, UTHealth Houston, USADetails: Candida spp are the most prevalent fungal pathogen causing infection in hospitalized patients in the US. This in vitro study performed at the University of Texas, Houston, compared SCY-247 and 7 other antifungal agents against 171 clinical yeast isolates.SCY-247 demonstrated antifungal activity against clinically relevant yeasts, including epidemiologically-relevant species such as Candida auris and fluconazole-resistant Candida parapsilosis. Title:The new triterpenoid antifungal SCY-247 retained activity against most echinocandin- and fluconazole-resistant Candida spp isolates: reduced susceptibility in C. glabrata isolates showing substitutions at the first amino acid in hotspot 1 FKS2 gene